SEC Comment Letter 0000000000-24-011496 to RENOVARO INC. (RENB) (CIK 0001527728) (LNAI)
RENOVARO INC. (RENB) (CIK 0001527728)
Date: Oct. 10, 2024 · CIK: 0001527728 · Accession: 0000000000-24-011496
AI Filing Summary & Sentiment
File numbers found in text: 001-38758
Letter
October 10, 2024 Mark DyBul Chief Executive Officer Renovaro Biosciences Inc. 2080 Century Park East, Suite 906 Los Angeles, CA 90067 Re:Renovaro Biosciences Inc. Form 10-K for the Fiscal Year Ended June 30, 2023 Filed October 2, 2023 File No. 001-38758 Dear Mark DyBul: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
October 10, 2024
Mark DyBul
Chief Executive Officer
Renovaro Biosciences Inc.
2080 Century Park East, Suite 906
Los Angeles, CA 90067
Re:Renovaro Biosciences Inc.
Form 10-K for the Fiscal Year Ended June 30, 2023
Filed October 2, 2023
File No. 001-38758
Dear Mark DyBul:
We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences